Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Probity Medical Research Corp

Neither a doctor nor a teaching hospital

Research payments

$5,799,728

473 payments

Through program year 2025, Probity Medical Research Corp is reported as receiving $5,799,728 in research payments, across 473 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $743,053 142
2024 Research $663,871 89
2023 Research $447,003 70
2022 Research $454,635 48
2021 Research $663,855 48
2020 Research $774,427 26
2019 Research $2,052,885 50

Breakdown

Who paid Research payments · program years 2019–2025
  1. Eli Lilly and Company $3,240,921 103 payments
  2. Pfizer Inc. $982,985 88 payments
  3. Takeda Pharmaceuticals U.S.A., Inc. $910,812 133 payments
  4. Janssen Research & Development, LLC $320,786 66 payments
  5. Acrotech Biopharma LLC $165,705 30 payments
  6. Sanofi US Services Inc. $88,409 32 payments
  7. Aclaris Therapeutics, Inc. $63,653 12 payments
  8. AbbVie, Inc. $23,899 5 payments
  9. Regeneron Pharmaceuticals, Inc. $2,559 4 payments
Studies the money was for Research payments · program years 2019–2025
  1. A 24-Week Multicenter, Randomized, Blinded, Parallel-Group Study Comparing the Efficacy and Safety of Ixekizumab to Guselkumab in Patients With Moderate-To-Severe Plaque Psoriasis $834,558 14 payments
  2. A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Operationally Seamless, Adaptive Phase 2/3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Severe Or Very Severe Alopecia Areata $768,515 7 payments
  3. Abrocitinib Expanded Access Protocol for the Treatment of Adolescents and Adults With Moderate to Severe Atopic Dermatitis $746,210 45 payments
  4. A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Severe Alopecia Areata $473,149 12 payments
  5. TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis $300,003 39 payments
  6. Assessment of Safety, Tolerability, and Efficacy of Ly3303560 in Early Symptomatic Alzheimer's Disease $290,484 6 payments
  7. A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 60 Weeks of Treatment With a Withdrawal and Retreatment Period $274,110 33 payments
  8. A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 52 Weeks of Treatment $248,755 49 payments
  9. A Multicenter, Long-Term Extension to Evaluate the Long-Term Safety and Maintenance of Treatment Effect of Ly3074828 in Patients With Moderate-To-Severe Plaque Psoriasis Oasis-3 $213,786 13 payments
  10. A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis $189,596 39 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record